Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients.
The increasing incidence of nosocomial candidal infections is a pivotal problem for patients who do not have neutropenia. In contrast with previous principles, candidemia--even in nonneutropenic patients--should be treated with systemic antifungal agents except in rare circumstances. Amphotericin B remains the agent of choice for treatment of hematogenously disseminated candidiasis and for candidemia, although the optimal dosage and duration of this therapy are poorly defined. Therapy with fluconazole is an alternative for patients who are intolerant to amphotericin B; the efficacy of fluconazole compared with that of amphotericin B in hematogenous candidal infections is unknown but is currently being evaluated. Removal of prosthetic devices that are infected with Candida is necessary in nearly all instances to cure the infection. Similarly, removal of an indwelling catheter whose use is associated with candidemia, as opposed to leaving the catheter in place during antifungal therapy, may increase survival rates of patients and lower their rates of complication. Antifungal prophylaxis may be useful for patients who are undergoing transplantation of an organ.
Edwards
J E
JE
Department of Medicine, Harbor-UCLA Medical Center, Torrance 90502.
Filler
S G
SG
D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D003428:Cross Infection / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D015725:Fluconazole / Q000627:therapeutic use*; D016469:Fungemia / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans
D000666:Amphotericin B; D015725:Fluconazole